Veradermics says oral minoxidil candidate VDPHL01 posts positive Phase 2 data in female hair loss
Veradermics, Incorporated
Veradermics, Incorporated MANE | 0.00 |
- Veradermics reported positive topline Phase 2 results from open-label Study 207 of VDPHL01 in female pattern hair loss.
- Mean non-vellus target area hair count rose 22.7 hairs/cm² with 4.5 mg once daily, 23.3 hairs/cm² with 4.5 mg twice daily at Month 6.
- AAIRS showed 88.9% (once daily) and 90.0% (twice daily) rated hair coverage “improved” or “much improved” at Month 6.
- Safety profile showed no treatment-related serious adverse events, no cardiac adverse events of special interest.
- Topline results from registration-directed Phase 2/3 Study 306 expected in 1H 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veradermics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607150700BIZWIRE_USPR_____20260715_BW636372) on July 15, 2026, and is solely responsible for the information contained therein.